Search Results

Milestone® Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia.

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024.

Milestone® Pharmaceuticals Inc. announced that the United States Food and Drug Administration accepted the Company’s New Drug Application on May 26, 2024 for CARDAMYST nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardia.

ReviR Therapeutics and Asieris Pharmaceuticals, a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases, announced a milestone was reached today in their ongoing collaboration.

Arrowhead Pharmaceuticals, Inc. announced a $50 million milestone payment was received from Royalty Pharma plc.

Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024 and provided a regulatory and corporate update.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, announced the commencement of several significant milestones.

Milestone ® Pharmaceuticals Inc. today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL.